ZURICH (Reuters) - Swiss drugmaker Roche (S:ROG) again extended its offer for shares of gene therapy specialist Spark Therapeutics (O:ONCE) to Dec. 16 as a regulatory review of the $4.3 billion (3.35 billion pounds) transaction drags on.
All terms and conditions of Roche's offer remain unchanged, it said in a statement on Monday.